Highest Research Award Given to Creators of Hemlibra
When the subcutaneous injectable medication Hemlibra first hit the market in 2017 it was heralded as a game changer for the hemophilia A community. Now in 2026 the three doctors who brought the drug to life are being celebrated for their work with one of the medical research profession’s highest honors. The Lasker Foundation of […]
Nasal Spray STIMATE Returning To Market This Fall
Ferring Pharmaceuticals has announced their nasal spray STIMATE will return to the market this fall following a six year absence. The nasal spray for Hemophilia A and von Willebrand Type 1 patients was voluntarily recalled in 2020 due to what the pharmaceutical company called a “packaging-related issue, which has now been resolved.” Ferring announced in […]
CSL Provides Update on HEMGENIX® Supply and Patient Access
The following is a letter from CSL. See the letter in its entirety here. Dear Hemophilia B Community, In March, we shared an update regarding HEMGENIX® (etranacogene dezaparvovec-drlb) availability and our efforts to support people living with hemophilia B while maintaining the highest quality standards for this one-time gene therapy. Since then, we have provided […]
Sanofi Provides a Statement on FDA Letter
On June 22, 2026, the Food and Drug Administration issued a warning letter to a facility in Ireland. Sanofi shared the following statement with Hemophilia Federation of America: Patient safety and the quality of our products are our highest priorities. We take the FDA Warning Letter issued to the Waterford (Ireland) facility with the utmost […]
Incyte Completes Acquisition of Vega Therapeutics, Expanding its Hematology Portfolio
The following announcement is from a press release from Incyte. Read the full press release here. Incyte announced July 6, 2026, it has completed its acquisition of Vega Therapeutics Inc., a wholly owned subsidiary of Star Therapeutics LLC. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease to Incyte’s hematology portfolio. […]
FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations
The following is an announcement from Pfizer: NEW YORK — On June 8 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI® (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients (ages 6 to 11 […]
Takeda Announces Important Product Supply Update of HEMOFIL and RECOMBINATE
Takeda has announced that as of March 2025, it has decided to globally discontinue HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Antihemophilic Factor (Recombinant)]. This was not a decision made lightly. Takeda understands that this directly impacts patients and they are here to support the hemophilia community during this transition. • […]
CSL Behring Provides Update on HEMGENIX Availability
CSL Behring today announced an important update on the availability of HEMGENIX® (etranacogene dezaparvovec-drlb) in the United States. CSL is currently experiencing a temporary global stockout of HEMGENIX® that will result in delays in treatment for some individuals in countries with established commercial access. We want to be very clear that this situation is not […]
Pfizer – Adverse Event in Clinical Trial
Pfizer has announced the death of a participant enrolled in the study of marstacimab in individuals with Hemophilia A or B, on December 14, 2025. Read more
US FDA Approved Takeda’s sBLA for VONVENDI
On Friday, September 7, 2025 the U.S. FDA approved Takeda’s supplemental Biologics License Application (sBLA) for VONVENDI to expand its indication for routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Disease (VWD), including those with Type 1 and 2 disease, and on-demand and perioperative management of bleeding in pediatric patients with VWD. […]
English 
Español de Puerto Rico